首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCL13 |
| Uniprot No | Q99616 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-98aa |
| 氨基酸序列 | QPDALNVPST CCFTFSSKKI SLQRLKSYVI TTSRCPQKAV IFRTKLGKEI CADPKEKWVQ NYMKHLGRKA HTLKT |
| 预测分子量 | 9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"CCL13 expression in a murine model of allergic asthma" - Smith et al.**
该研究探讨了CCL13重组蛋白在小鼠哮喘模型中的作用，发现其通过招募嗜酸性粒细胞和Th2细胞加剧气道炎症，提示其在过敏性疾病中的潜在治疗靶点。
2. **"Chemokine CCL13 promotes tumor growth via angiogenesis in colorectal cancer" - Li et al.**
作者利用重组CCL13蛋白验证了其通过激活VEGF通路促进结直肠癌血管生成和肿瘤进展的机制，为癌症治疗提供了新方向。
3. **"CCL13 mediates viral-induced lung inflammation through macrophage activation" - Gonzalez et al.**
研究显示，重组CCL13蛋白在呼吸道合胞病毒(RSV)感染中驱动巨噬细胞极化，导致肺部炎症加重，揭示了其在病毒感染免疫调控中的作用。
4. **"Structural and functional characterization of recombinant human CCL13" - Patel et al.**
该文献通过生物化学和细胞实验解析了重组人CCL13蛋白的结构，并证实其与受体CCR2/CCR3结合后激活ERK/STAT信号通路的功能特性。
CCL13 (C-C motif chemokine ligand 13), also known as monocyte chemoattractant protein-4 (MCP-4), is a small secretory protein belonging to the CC chemokine family. It plays a critical role in immune regulation by recruiting leukocytes, including monocytes, eosinophils, dendritic cells, and T lymphocytes, to sites of inflammation or infection. CCL13 exerts its biological effects through interaction with chemokine receptors CCR2. CCR3. and CCR5. activating downstream signaling pathways that regulate cell migration and immune responses. Dysregulation of CCL13 has been implicated in chronic inflammatory diseases (e.g., asthma, atopic dermatitis), autoimmune disorders, and cancer progression.
Recombinant CCL13 protein is engineered using expression systems such as *E. coli* or mammalian cells to ensure high purity and bioactivity. The recombinant form typically retains the conserved structural features of natural CCL13. including a conserved N-terminal region critical for receptor binding and a characteristic β-sheet fold stabilized by disulfide bonds. Its production enables precise studies of chemokine-receptor interactions, immune cell trafficking mechanisms, and disease pathogenesis *in vitro* and *in vivo*.
In research, recombinant CCL13 is widely used to model inflammatory processes, screen potential therapeutic agents targeting chemokine pathways, and investigate cross-talk between immune cells and tumor microenvironments. Its stability and reproducibility make it valuable for drug discovery, particularly in developing inhibitors for inflammatory diseases or metastasis. However, functional variations may occur depending on post-translational modifications in different expression systems, necessitating careful validation for specific applications.
×
